Buckley Wealth Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 48,564 shares of the company’s stock after selling 582 shares during the period. Johnson & Johnson accounts for about 3.1% of Buckley Wealth Management LLC’s portfolio, making the stock its 10th largest position. Buckley Wealth Management LLC’s holdings in Johnson & Johnson were worth $8,579,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently added to or reduced their stakes in JNJ. Nordwand Advisors LLC purchased a new position in Johnson & Johnson in the 4th quarter worth about $785,273,000. Savant Capital LLC grew its holdings in Johnson & Johnson by 8,568.8% during the 4th quarter. Savant Capital LLC now owns 3,630,127 shares of the company’s stock worth $29,637,000 after acquiring an additional 3,588,251 shares in the last quarter. Edmp Inc. grew its holdings in Johnson & Johnson by 17,222.9% during the 4th quarter. Edmp Inc. now owns 3,223,265 shares of the company’s stock worth $18,247,000 after acquiring an additional 3,204,658 shares in the last quarter. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. Finally, GQG Partners LLC grew its holdings in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.20% of the company’s stock.
Analysts Set New Price Targets
Johnson & Johnson Stock Performance
JNJ opened at $158.91 on Monday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $183.35. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $412.96 billion, a PE ratio of 33.24, a P/E/G ratio of 2.71 and a beta of 0.53. The firm has a 50 day moving average of $159.70 and a two-hundred day moving average of $166.20.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $2.67 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is 94.56%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Warren Buffett Boosts Occidental Stake, Adds 3.46 Million Shares
- What’s Behind The Recent Meteoric Rise Of Tingo Group
- Is PulteGroup Overbought After Double-Digit Gains?
- Netflix Stock Just Had Its Largest Intraday Gain Since 2022
- Analyst Flags Concerns About P&G Growth Despite Earnings Beat
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.